Previous 10 | Next 10 |
home / stock / mrna / mrna articles
The S&P 500 Index has risen by 19% year-to-date, with three weeks remaining in the year and just a five percentage point gap from the all-time ...
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 21.8% on an annualized basis producing an average annual return of 33.32...
Texas Attorney General Ken Paxton has filed a lawsuit against Pfizer Inc (NYSE: PFE), alleging the pharmaceutical giant misrepr...
Moderna Inc (NASDAQ: MRNA) shares slipped on Tuesday trading after the European Patent Office said a contested mRNA patent owned by Moderna is...
BioNTech SE (NASDAQ: BNTX) has reported Q3 revenues of €895.3 million ($974.49 million), sharply down from €3.461 billion a year ago...
Moderna Inc (NASDAQ: MRNA) posted a loss for the third quarter on Thursday. Moderna reported a quarterly loss of $(9.53), down from EPS income of ...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
On Thursday, Cathie Wood-led Ark Invest made notable adjustments to its holdings, with a significant sale of DraftKings Inc (NASDAQ:DKNG) shares an...
Risk appetite is surging again Thursday on Wall Street, with investors welcoming the Federal Reserve’s decision to keep rates unchanged and F...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...